Shanti Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 11-12-2024
- Paid Up Capital ₹ 1.41 Cr
as on 11-12-2024
- Company Age 31 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 2.20 Cr
as on 11-12-2024
- Revenue -31.96%
(FY 2023)
- Profit 1833.24%
(FY 2023)
- Ebitda -10.22%
(FY 2023)
- Net Worth 2.40%
(FY 2023)
- Total Assets -4.53%
(FY 2023)
About Shanti Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.41 Cr.
The company has closed loans amounting to ₹2.20 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Kamlesh Gupta, Rakesh Gupta, and Om Prakash serve as directors at the Company.
- CIN/LLPIN
U74899DL1993PTC051735
- Company No.
051735
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jan 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Shanti Drugs?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamlesh Gupta  | Director | 01-Sep-2003 | Current |
| Rakesh Gupta | Director | 15-Jan-1993 | Current |
| Om Prakash | Director | 11-Sep-2020 | Current |
Financial Performance of Shanti Drugs.
Shanti Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 31.96% decrease. The company also saw a substantial improvement in profitability, with a 1833.24% increase in profit. The company's net worth moved up by a moderate rise of 2.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shanti Drugs?
Unlock access to Shanti Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Delhi Nagrik Sehkari Bank Ltd. Creation Date: 08 Jun 2010 | ₹2.20 Cr | Satisfied |
How Many Employees Work at Shanti Drugs?
Shanti Drugs has a workforce of 5 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shanti Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shanti Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
